Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multiple-Center, Multiple-Dose, Randomized, Active Comparator-Controlled, Double-Masked, Parallel Group, 36-Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema

NCT02699450 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02699450
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02699450 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multiple-Center, Multiple-Dose, Randomized, Active Comparator-Controlled, Double-Masked, Parallel Group, 36-Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
April 27, 2016
Completion date
December 14, 2017
Enrollment
229 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema